Abstract-␤ 2 -Glycoprotein I is a single-chain 50-kDa protein that circulates in plasma at a concentration of Ϸ200 g/mL.
␤ 2 -Glycoprotein I is a single-chain 50-kDa lipid-binding serum glycoprotein first identified in 1961. 1 The plasma concentration of this glycoprotein is Ϸ4 mol/L (200 g/mL), of which one third is bound to lipoproteins. 2 Because of its association with lipoprotein fractions, ␤ 2 -glycoprotein I is also referred to as apolipoprotein H. Human ␤ 2 -glycoprotein I was completely sequenced and cloned, and the gene has been localized to chromosome 17. 3-5 ␤ 2 -Glycoprotein I is a member of the so-called "complement control protein" (CCP) superfamily, 6, 7 whose members are identified by the presence of Ն1 repeats of Ϸ60 amino acid sequences characterized by a relatively invariant arrangement of 2 disulfide bonds and a number of other highly conserved residues. ␤ 2 -Glycoprotein I is made up of 5 complement control protein repeats, the fifth of which has a relatively unusual pattern of 3 disulfide bridges and contains a positively charged sequence, CKNKEKKC, that has been shown to be a binding site for anionic phospholipid. 8 The physiological role of ␤ 2 -glycoprotein I remains uncertain. It has been reported to bind negatively charged surfaces, including anionic phospholipid vesicles, 9 platelets, 10 platelet-derived microparticles, 11 and apoptotic cells. 12 Binding is accompanied in vitro by inhibition of phospholipid-dependent coagulation tests. 13 Here, we show that ␤ 2 -glycoprotein I promotes the binding and internalization of anionic phospholipid vesicles by macrophages.
Methods
RPMI medium 1640, cholesterol, and phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma Chemical Co. Bovine brain phosphatidylserine (PS), egg phosphatidylcholine (PC), heart cardiolipin, liver phosphatidylinositol, liver phosphatidylethanolamine, and N- [4- Isolation of ␤ 2 -Glycoprotein I ␤ 2 -Glycoprotein I was isolated from normal citrated plasma as described previously, 14 with some modifications. Plasma (100 mL) was mixed with 2.5 mL 70% (vol/vol) perchloric acid, stirred gently at 4°C for 15 minutes, and centrifuged at 13 000g for 15 minutes at 4°C. After the supernatant was neutralized to pH 7.0 with 12.5 mol/L NaOH, 43 g of ammonium sulfate powder was added, and the mixture was stirred at 4°C for 30 minutes. After centrifugation at 13 000g for 15 minutes at 4°C, the precipitate was dissolved in 0.03 mol/L NaCl, 0.02 mol/L Tris-HCl, pH 8.0, and dialyzed against the same buffer. The sample was applied to a column of heparinSepharose (2ϫ15 cm) that was washed sequentially with 400 mL 0.05 mol/L NaCl, 0.02 mol/L Tris, pH 8.0, and 400 mL 0.15 mol/L NaCl, 0.02 mol/L Tris, pH 8.0, and then eluted with 0.35 mol/L NaCl, 0.02 mol/L Tris, pH 8.0. The ␤ 2 -glycoprotein I-containing peak was dialyzed against a buffer containing 0.05 mol/L HEPES, 0.05 mol/L NaCl, pH 7.0, applied to a Mono S column (Pharmacia Biotech Inc), and eluted with 0.05 to 0.5 mol/L salt gradient in the same buffer. The ␤ 2 -glycoprotein I peak was collected and dialyzed against HBS (0.15 mol/L NaCl, 0.02 mol/L HEPES, pH 7.4). ␤ 2 -Glycoprotein I was iodinated with [ 125 I]NaI by the Iodogen method. 15 
Phospholipid Vesicles
Phospholipid-cholesterol vesicles were prepared with a molar ratio of phospholipid to cholesterol of 1:0.75. The phospholipid used was either 100% PS or PC. When mixed vesicles were prepared, the molar concentration of phospholipid was the same with different proportions of PS and PC. Vesicles were prepared with a nonexchangeable tracer, [ 3 H]cholesteryl hexadecyl ether (Amersham Co), to quantify the binding of phospholipid. 16 Phospholipid and cholesterol were dissolved in chloroform and evaporated to dryness in a glass ampoule with a gentle stream of dry nitrogen and suspended in 5 mL of buffer (0.15 mol/L NaCl, 0.01 mol/L HEPES, pH 7.4). The suspension was deaerated by bubbling with dry nitrogen for 15 minutes. The ampoule was flame-sealed and placed in a water bath, and the phospholipid suspension was emulsified by sonication (Heat System Ultrasonics, Inc) for 45 minutes, the temperature being maintained at 20°C to 25°C by the addition of ice to the bath. The phospholipid vesicles were then passed through a 0.2-m filter (Gelman Sciences) and stored at 4°C. The phospholipid vesicles were examined by electron microscopy and negative staining with uranyl acetate and shown to be almost exclusively unilamellar vesicles Ͻ200 nm in diameter. Lipid peroxidation products in the phospholipid preparations were measured by the thiobarbituric acid method as described before. 17 The lipid peroxide contents were Ͻ1.07Ϯ0.03 (nϭ3) nmol/mg of phospholipid. Fluorescent vesicles had the same lipid composition with the addition of NBD-PC (2% of the total phospholipid, wt/wt) but without the tracer.
Cell Lines and Macrophages
THP-1 cells obtained from the American Type Culture Collection were grown in tissue culture flasks under 5% CO 2 at 37°C in RPMI 1640 medium containing 10% heat-inactivated FCS. The cells were treated with PMA (100 nmol/L), plated in 24-well plates (Costar) (2ϫ10 6 cells/plate), and allowed to differentiate for 72 hours. Human monocyte-derived tissue macrophages were prepared by culturing peripheral blood monocytes isolated by the Ficoll-Hypaque gradient method, as previously described. 18 Platelet-derived microvesicles were prepared as described before. 19, 20 
Phospholipid Binding Assay
Tissue culture wells containing 2ϫ10 6 adherent, differentiated THP-1 cells or 0.5ϫ10 6 monocyte-derived macrophages were washed in PBS and replaced with serum-free Medium 199 containing various concentrations of [ 3 H]cholesterol-labeled phospholipid vesicles. The medium contains 1 mmol/L Ca 2ϩ . ␤ 2 -Glycoprotein I was added and incubated at 37°C for 4 hours. At the end of the incubation period, the cells were rapidly washed 6 times in serumfree Medium 199. The cells were solubilized by incubation in a 200-L volume of 2% SDS for 20 minutes. The cell-associated radioactivity was counted in a scintillation counter. To correct for nonspecific binding, in each experiment, parallel wells containing tissue culture medium without cells were incubated with ␤ 2 -glycoprotein I and anionic phospholipid vesicles, and the binding was subtracted from total binding.
Flow Cytometric Analysis of Incorporation of Phospholipid
Phorbol ester-stimulated THP-1 cells were incubated with fluorescent-PS vesicles (100 mol/L) in serum-free medium in the presence or absence of ␤ 2 -glycoprotein I (100 mol/L). After 4 hours of incubation at 37°C, the cell layers were washed in serum-free medium and trypsinized. The single-cell suspensions of THP-1 cells were analyzed for cell-associated fluorescence by flow cytometry.
Internalization of
125 I-Labeled ␤ 2 -Glycoprotein I
THP-1 cells (15ϫ10 6 ) were seeded in 60-mm tissue culture dishes (Corning Glass Works) in the presence of 100 nmol/L PMA. Three days later, cell layers were washed 3 times in serum-free medium, and 1 mL of medium containing 3% BSA and 400 nmol/L 125 I-␤ 2 -glycoprotein I was added. After incubation for 1 hour at 37°C, the overlying medium was removed, and the cells were incubated for 30 minutes at 4°C in tissue culture medium containing 0.25% Pronase, which removes cell surface ligands and also detaches the cells. The detached cells were separated from the medium by centrifugation and washed 3 times. Radioactivity associated with the cell pellet (internalized Pronace-insensitive ligand) was determined in a gamma counter.
Results

Effect of ␤ 2 -Glycoprotein I on the Binding of Anionic Phospholipid Vesicles
As shown in Figure 1A , when phorbol ester-stimulated THP-1 cells were incubated with PS vesicles (75 mol/L) at 37°C in the presence of ␤ 2 -glycoprotein I, the vesicle binding was linear for 2 hours and reached saturation at 2.5 to 3 hours. In the absence of ␤ 2 -glycoprotein I, the vesicle binding was decreased by 90%. Binding was dependent on the concentrations of both PS vesicles ( Figure 1B ) and ␤ 2 -glycoprotein I ( Figure 1C ) and was optimal at 150 mol/L of PS and at 100 g/mL of ␤ 2 -glycoprotein I. The effect of ␤ 2 -glycoprotein I on PS vesicle binding was temperature-dependent ( Figure  1D ): PS binding at 4°C was Ϸ20% of the binding at 37°C. 
Effect of Phospholipid Composition on ␤ 2 -Glycoprotein I-Dependent Binding of Anionic Phospholipid Vesicles
Anionic phospholipid vesicles containing PS, phosphatidic acid, or cardiolipin ( Figure 4) inhibited binding of the radiolabeled PS vesicles, whereas neutral or zwitterionic phospholipid vesicles composed of PC (Figure 4) , sphingomyelin, or phosphatidylethanolamine (data not shown) had no effect. Incorporation of dicetyl phosphate or stearylamine to give a net negative or positive charge to the phospholipid vesicles, respectively, had no significant effect on the binding, suggesting that charge alone does not confer ␤ 2 -glycoprotein I-dependent binding (data not shown). Plateletderived microvesicles have previously been shown to contain anionic phospholipid on their outer surface. 20 Inhibition of ␤ 2 -glycoprotein I-dependent binding of PS vesicles is consistent with these observations (Figure 4 ).
␤ 2 -Glycoprotein I-Dependent Incorporation of Anionic Phospholipid
To determine whether the enhanced binding of anionic phospholipid vesicles to macrophage membranes is associated with incorporation of phospholipids in the membrane, fluorescent PS vesicles containing NBD-PC as fluorescent tracer were incubated with phorbol ester-stimulated THP-1 cells in the presence of ␤ 2 -glycoprotein I. The cell-bound phospholipid vesicles were analyzed by flow cytometry. The presence of ␤ 2 -glycoprotein I resulted in increased incorporation of PS-containing fluorescent phospholipids ( Figure 5 ). No significant effect of ␤ 2 -glycoprotein I was seen when cells were incubated with PC-containing vesicles.
PS Vesicle-Dependent Internalization of ␤ 2 -Glycoprotein I by THP-1 Cells
To determine whether incubation of ␤ 2 -glycoprotein I with PS vesicles results in the internalization of ␤ 2 -glycoprotein I, 125 I-labeled ␤ 2 -glycoprotein I (400 nmol/L) was incubated with phorbol ester-stimulated THP-1 cells in the presence of PS or PC vesicles. There was a dose-dependent increase in the internalization of ␤ 2 -glycoprotein I by PS vesicles, whereas PC vesicles had no significant effect ( Figure 6 ).
Discussion
The experiments reported here show that ␤ 2 -glycoprotein I promotes the binding of anionic phospholipid vesicles to macrophages. This effect is saturable, temperaturedependent, and specific for anionic phospholipids. Cell surfaces containing anionic phospholipids, such as plateletderived microvesicles, inhibit this binding. These studies suggest a physiological function for ␤ 2 -glycoprotein I in the clearance of anionic phospholipid-containing procoagulant surfaces from the circulation. The complex of anionic phospholipid vesicles and ␤ 2 -glycoprotein I is recognized by a putative cell surface receptor on macrophages or possibly other cells. These complexes are taken into a receptormediated pathway, and this may play a role in the removal of procoagulant anionic phospholipid surfaces from the circulation. Wurm et al 21 showed that infusion of ␤ 2 -glycoprotein I in rats results in an accelerated clearance of triglyceride-rich vesicles from the circulation, and Chonn et al 22 showed ␤ 2 -glycoprotein I-dependent clearance of anionic phospholipid vesicles in mice. Our results showing that ␤ 2 -glycoprotein I enhances the binding of anionic phospholipid to macrophages are consistent with these reports.
Nishikawa et al 23 first reported in 1990 that macrophage scavenger receptor mediates the binding of anionic phospholipid to mouse peritoneal macrophages. However, using
Chinese hamster ovary cells transfected with class A bovine macrophage scavenger receptor, Lee et al 24 could not demonstrate this effect. The possible role of ␤ 2 -glycoprotein I was not studied, and it is possible that the presence of ␤ 2 -glycoprotein I might have given these conflicting results. Recently, additional receptors, distinct from the type A scavenger receptors that bind oxidized LDL and PS vesicles, have been identified. [25] [26] [27] At least 1 of these receptors also binds oxidized red blood cells and apoptotic cells by a PSdependent mechanism. 28 The precise identification of the receptor(s) that mediates ␤ 2 -glycoprotein I-dependent binding of anionic phospholipid vesicles will require transfection studies with these candidate receptors.
Decreased levels of ␤ 2 -glycoprotein I have been reported in disseminated intravascular coagulation, a condition associated with platelet activation and generation of microvesicles in vivo. 29, 30 In addition, patients with antiphospholipid antibody syndrome have in their serum immunoglobulins that react with anionic phospholipids in a variety of immunological assays. 31 The precise antigenic target of antiphospholipid antibodies, whether neoepitopes induced in protein, such as ␤ 2 -glycoprotein I, after phospholipid or surface binding or a complex conformational epitope consisting of protein and phospholipid, has not been resolved and is a subject of controversy. 9, [31] [32] [33] [34] At least some of these antibodies recognize a complex epitope consisting of anionic phospholipid bound to ␤ 2 -glycoprotein I and other phospholipid-binding proteins. 31, 32 These antibodies may impair the clearance of ␤ 2 -glycoprotein I-dependent binding of anionic phospholipid vesicles by interfering with the binding and/or internalization of procoagulant anionic phospholipid surfaces of activated platelets and apoptotic cells, allowing prolonged survival of procoagulant anionic phospholipid vesicles in the circulation. In fact, increased levels of platelet-derived microvesicles have been reported in the plasma of patients with the antiphospholipid antibody syndrome. 35 However, hereditary deficiency of ␤ 2 -glycoprotein I does not appear to be associated with risk of a hypercoagulable state. 36 Thrombosis is a complex multigene phenotype. Because of the large number of genes that influence this phenotype, teasing out the role of the ␤ 2 -glycoprotein I locus will be difficult. One would expect that ␤ 2 -glycoprotein I deficiency would contribute to a prothrombotic tendency when it is coincident with other genetic risks for thrombosis, for example, heterozygosity for factor V Leiden. When these studies were in progress, Balasubramanian et al 37 reported that human ␤ 2 -glycoprotein I did not stimulate the uptake of PS vesicles by mouse macrophages. However, the concentration of ␤ 2 -glycoprotein I used in that study (5 g/mL) was at least 10 times lower than the physiological concentration. Furthermore, species differences could account for the differences. Manfredi et al 38 did not find a significant role for ␤ 2 -glycoprotein I in the phagocytosis of apoptotic T cells by macrophages. They used 10% serum as a source of ␤ 2 -glycoprotein I, a suboptimal concentration for enhanced binding. Furthermore, the extent of PS exposure may vary under different conditions, giving rise to negative effects.
In conclusion, our results show that ␤ 2 -glycoprotein I promotes the binding of anionic phospholipid-containing vesicles by a macrophage. This mechanism may have a physiological role in removing procoagulant phospholipid vesicles or cell fragments from circulation.
